S&P 500   4,320.06
DOW   33,963.84
QQQ   356.31
3 Blue Chip Safe Havens to Shield Your Portfolio
Would Buffett Approve of This Growth Strategy? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: Wall Street inches lower hinting that sustained market sell-off may continue
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Would Buffett Approve of This Growth Strategy? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
S&P 500   4,320.06
DOW   33,963.84
QQQ   356.31
3 Blue Chip Safe Havens to Shield Your Portfolio
Would Buffett Approve of This Growth Strategy? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: Wall Street inches lower hinting that sustained market sell-off may continue
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Would Buffett Approve of This Growth Strategy? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
S&P 500   4,320.06
DOW   33,963.84
QQQ   356.31
3 Blue Chip Safe Havens to Shield Your Portfolio
Would Buffett Approve of This Growth Strategy? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: Wall Street inches lower hinting that sustained market sell-off may continue
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Would Buffett Approve of This Growth Strategy? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
S&P 500   4,320.06
DOW   33,963.84
QQQ   356.31
3 Blue Chip Safe Havens to Shield Your Portfolio
Would Buffett Approve of This Growth Strategy? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: Wall Street inches lower hinting that sustained market sell-off may continue
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Would Buffett Approve of This Growth Strategy? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
NASDAQ:SRDX

Surmodics (SRDX) Stock Forecast, Price & News

$32.44
-0.31 (-0.95%)
(As of 09/22/2023 06:55 PM ET)
Compare
Today's Range
$32.29
$33.10
50-Day Range
$31.08
$38.36
52-Week Range
$16.00
$39.41
Volume
37,700 shs
Average Volume
120,038 shs
Market Capitalization
$458.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.50

Surmodics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
83.4% Upside
$59.50 Price Target
Short Interest
Healthy
0.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.52
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.22) to ($0.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

526th out of 961 stocks

Surgical & Medical Instruments Industry

60th out of 96 stocks


SRDX stock logo

About Surmodics (NASDAQ:SRDX) Stock

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

SRDX Price History

SRDX Stock News Headlines

Comparing Surmodics (NASDAQ:SRDX) & Arch Therapeutics (OTCMKTS:ARTH)
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Needham Upgrades Surmodics (SRDX)
Surmodics (NASDAQ: SRDX)
See More Headlines
Receive SRDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

SRDX Company Calendar

Last Earnings
8/02/2023
Today
9/25/2023
Fiscal Year End
9/30/2023
Next Earnings (Estimated)
11/08/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:SRDX
CUSIP
86887310
Employees
447
Year Founded
1979

Price Target and Rating

Average Stock Price Forecast
$59.50
High Stock Price Forecast
$69.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+83.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-27,270,000.00
Pretax Margin
-1.16%

Debt

Sales & Book Value

Annual Sales
$99.95 million
Book Value
$7.75 per share

Miscellaneous

Free Float
13,074,000
Market Cap
$458.38 million
Optionable
Optionable
Beta
1.14

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Gary R. MaharajMr. Gary R. Maharaj (Age 60)
    CEO, Pres & Director
    Comp: $1.1M
  • Mr. Timothy J. Arens (Age 56)
    Sr. VP of Fin. & Information Technology and CFO
    Comp: $545.83k
  • Mr. Gordon S. Weber (Age 60)
    Sr. VP of Legal, Gen. Counsel & Sec.
    Comp: $519.6k
  • Mr. Charles W. OlsonMr. Charles W. Olson (Age 59)
    Sr. VP & Pres of Medical Device Coatings
    Comp: $523.12k
  • Ms. Teryl L. W. Sides (Age 53)
    Sr. VP & Pres of Vascular Interventions
    Comp: $613.02k
  • Mr. John D. Manders (Age 42)
    Corp. Controller, VP of Fin. & Principal Accounting Officer
  • Mr. Joseph J. StichMr. Joseph J. Stich (Age 58)
    Sr. VP of HR & Pres of In Vitro Diagnostics













SRDX Stock - Frequently Asked Questions

Should I buy or sell Surmodics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRDX shares.
View SRDX analyst ratings
or view top-rated stocks.

What is Surmodics' stock price forecast for 2023?

2 equities research analysts have issued 12-month price objectives for Surmodics' stock. Their SRDX share price forecasts range from $50.00 to $69.00. On average, they predict the company's share price to reach $59.50 in the next twelve months. This suggests a possible upside of 83.4% from the stock's current price.
View analysts price targets for SRDX
or view top-rated stocks among Wall Street analysts.

How have SRDX shares performed in 2023?

Surmodics' stock was trading at $34.12 at the beginning of 2023. Since then, SRDX stock has decreased by 4.9% and is now trading at $32.44.
View the best growth stocks for 2023 here
.

When is Surmodics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our SRDX earnings forecast
.

How were Surmodics' earnings last quarter?

Surmodics, Inc. (NASDAQ:SRDX) released its earnings results on Wednesday, August, 2nd. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.98. The company had revenue of $52.48 million for the quarter, compared to the consensus estimate of $26.70 million. Surmodics had a negative trailing twelve-month return on equity of 8.34% and a negative net margin of 17.58%.

What ETF holds Surmodics' stock ?

Invesco Nasdaq Future Gen 200 ETF holds 1,909 shares of SRDX stock, representing 0.85% of its portfolio.

What guidance has Surmodics issued on next quarter's earnings?

Surmodics issued an update on its FY 2023 earnings guidance on Saturday, August, 5th. The company provided earnings per share guidance of -$0.29--$0.14 for the period, compared to the consensus estimate of -$1.30. The company issued revenue guidance of $103.00 million-$106.00 million, compared to the consensus revenue estimate of $116.95 million.

What is Gary Maharaj's approval rating as Surmodics' CEO?

8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Surmodics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX).

What is Surmodics' stock symbol?

Surmodics trades on the NASDAQ under the ticker symbol "SRDX."

Who are Surmodics' major shareholders?

Surmodics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.12%), Renaissance Technologies LLC (4.18%), Segall Bryant & Hamill LLC (2.69%), Dimensional Fund Advisors LP (2.63%), Acadian Asset Management LLC (2.11%) and Kennedy Capital Management LLC (2.08%). Insiders that own company stock include Charles W Olson, Charles W Olson, David Dantzker, Gary R Maharaj, John D Manders, Jose H Bedoya, Jose H Bedoya, Joseph J Stich, Joseph J Stich and Ronald B Sr Kalich Sr.
View institutional ownership trends
.

How do I buy shares of Surmodics?

Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surmodics' stock price today?

One share of SRDX stock can currently be purchased for approximately $32.44.

How much money does Surmodics make?

Surmodics (NASDAQ:SRDX) has a market capitalization of $458.38 million and generates $99.95 million in revenue each year. The company earns $-27,270,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

How many employees does Surmodics have?

The company employs 447 workers across the globe.

How can I contact Surmodics?

Surmodics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The official website for the company is www.surmodics.com. The company can be reached via phone at (952) 500-7000, via email at ir@surmodics.com, or via fax at 952-500-7001.

This page (NASDAQ:SRDX) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -